KINETA
Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold. Kineta was founded in 2008 and is based in Seattle, Washington.
KINETA
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2008-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.kinetabio.com
Total Employee:
11+
Status:
Active
Contact:
(206)378-0400
Total Funding:
81.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving
Similar Organizations
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Charles Magness Co-Founder,President @ Kineta
Co-Founder,President
2007-01-01
Craig Philips President @ Kineta
President
2013-01-01
Shawn Iadonato Chief Executive Officer @ Kineta
Chief Executive Officer
2016-01-01
Michael Banks CFO @ Kineta
CFO
Ken North SVP, Corporate Development @ Kineta
SVP, Corporate Development
2008-11-01
Eric Tarcha SVP Translational Development @ Kineta
SVP Translational Development
Jacques Bouchy SVP Business Development and Corporate Communications @ Kineta
SVP Business Development and Corporate Communications
2016-01-01
Thierry Guillaudeux Executive Vice President and Chief Scientific Officer @ Kineta
Executive Vice President and Chief Scientific Officer
2022-02-01
Founder
Investors List
Cheongbo Industrial Co. (CBI)
Cheongbo Industrial Co. (CBI) investment in Corporate Round - Kineta
SCHLAEPFER FAMILY FOUNDATION
SCHLAEPFER FAMILY FOUNDATION investment in Venture Round - Kineta
Wellcome Trust
Wellcome Trust investment in Grant - Kineta
SFC Capital
SFC Capital investment in Venture Round - Kineta
Keiretsu Forum
Keiretsu Forum investment in Venture Round - Kineta
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Kineta
Keiretsu Forum Northwest
Keiretsu Forum Northwest investment in Venture Round - Kineta
Keiretsu Capital
Keiretsu Capital investment in Series B - Kineta
AngelMD
AngelMD investment in Funding Round - Kineta
RJ Jones
RJ Jones investment in Venture Round - Kineta
Newest Events participated
Participated in 15th annual Future in Review Conference
on 2017-10-10 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-28 | Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer |
Official Site Inspections
http://www.kinetabio.com Semrush global rank: 5.59 M Semrush visits lastest month: 1.52 K
Unable to get host informations!!!
More informations about "Kineta"
About Us – Kineta Inc.
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate …See details»
Kineta - Crunchbase Company Profile & Funding
Contact Email info@kinetabio.com Phone Number (206)378-0400 Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that …See details»
Overview - Kineta Inc.
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing …See details»
Kineta - Overview, News & Similar companies | ZoomInfo.com
Explore Complete Organization Structure. Is Kineta your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... (206) 378-0400 Website: kinetabio.com …See details»
Kineta - LinkedIn
Kineta | 3,679 followers on LinkedIn. KA (Nasdaq) Developing next-generation immunotherapies for cancer patients! | Kineta is a clinical stage biotechnology company with a mission to develop next ...See details»
Kineta, Inc. | Seattle, WA, USA Startup - Gust
Website kinetabio.com; Company Summary Kineta is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our …See details»
Kineta Announces Formation of New Immuno-oncology Focused …
SEATTLE, April 21, 2020 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and …See details»
Kineta Company Profile - Office Locations, Competitors, Revenue …
Oct 4, 2024 Kineta has 5 employees at their 1 location. See insights on Kineta including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 …
Jan 17, 2024 In the VISTA-101 trial (NCT05708950), a total of 18 patients have been dosed with KVA12123. 15 patients with advanced solid tumors were enrolled in the first four monotherapy …See details»
Working At Kineta: Company Overview and Culture - Zippia
Kinetabio.com. Organization Type. Private. Social Media. Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating …See details»
Kineta Announces Restructuring and Exploration of Strategic ...
SEATTLE, Feb. 29, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer …See details»
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA …
SEATTLE, June 1, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the …See details»
Kineta Enters Research Collaboration and License Agreement with …
SEATTLE, Dec. 17, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with …See details»
Kineta Reports Full Year 2023 Financial Results and Provides …
Mar 21, 2024 Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the …See details»
Kineta Announces First Patient Dosed in Phase 1/2 Clinical
Apr 12, 2023 For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook. KVA12123 (formerly referred to as KVA12.1) is expected …See details»
Kineta Expands Board of Directors with Biotech Industry Leaders …
SEATTLE, June 28, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer …See details»
Kineta Receives Regulatory Approval for Initiation of Phase 1 …
SEATTLE, Aug. 12, 2020 /PR Newswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology,...See details»
Kinea Bio Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Kinea Bio. Use the PitchBook Platform to explore the full profile.See details»
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 ...
Nov 8, 2024 For more information on Kineta, please visit www.kinetabio.com. Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 has …See details»